Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation

Completed · Phase 2 · Has a placebo group

Conditions studied: Smoking

In brief

Treatment of smokers with a tricyclic antidepressant, nortriptyline, can reduce tobacco withdrawal symptoms and increases long term cessation rates when combined with transdermal nicotine and a behavioral cessation programs. The study is a placebo-controlled, randomized, parallel group trial in which smokers aged 18-70 will be subject to the combination of oral and patch treatments.

Key facts

Study ID

NCT00018148

Run by

US Department of Veterans Affairs

People needed

158

Starts

1998-04-01

Expected to finish

2003-01-01

Last updated by the study team

2010-09-15

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged 18-70,
• smoking > 10 cigarettes per day,
• no current major depression,
• no concurrent psychiatric medications

Where it is running

• VA Eastern Colorado Health Care System, Denver — Denver, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.